Latest news with #Techcyte
Associated Press
03-06-2025
- Business
- Associated Press
Austria's Tyrolpath Leads Europe with First Clinical Adoption of Techcyte's SureView™
Tyrolpath launches Europe's first SureView™ installation, combining AI, imaging, and automation for high-volume cervical cytology. 'Dr. Obrist and his team are pioneers in adopting new technologies to advance patient care, and we are proud to support their vision with our AI-driven solutions.'— Ben Cahoon, Chief Executive Officer of Techcyte OREM, UT, UNITED STATES, June 3, 2025 / / -- Techcyte, leader in AI-powered digital pathology, announced today the first European clinical implementation of its Techcyte SureView™ cervical cytology solution at Tyrolpath, one of the largest private pathology laboratories in Austria. In partnership with BD, Techcyte's exclusive global distributor for Techcyte SureView™, this milestone marks a significant advancement in the digital transformation of cervical cancer screening in Europe. Tyrolpath, located in Zams, Austria, processes hundreds of thousands of Pap smears annually. To manage this volume, and lay the foundation for future diagnostic applications, Tyrolpath acquired the Pramana Spectral HT-4 scanner — the only open, multipurpose whole slide imaging system to offer smart, inline, volumetric scanning, providing high-throughput capacity, redundancy, and the flexibility to support multiple indications. The lab has integrated Techcyte's SureView™ platform alongside BD's SurePath™ liquid-based cytology, creating an automated, end-to-end cervical cancer screening workflow from sample collection through digital review. 'We are thrilled to see Tyrolpath leading the way in Europe,' said Ben Cahoon, Chief Executive Officer of Techcyte. 'Dr. Obrist and his team are pioneers in adopting new technologies to advance patient care, and we are proud to support their vision with our AI-driven solutions.' Dr. Peter Obrist, owner of Tyrolpath and a key opinion leader in cytology, remarked, 'SureView™ brings a new level of confidence to cervical screening. The combination of BD SurePath™ preparation, Pramana's high-quality imaging, and Techcyte's AI analysis enables us to maintain the highest diagnostic standards while preparing for the future of digital pathology.' Sandra Knöthig, Product Manager Women'sHealth & Cancer C&EE from BD added, 'This collaboration marks an important step in the evolution of cervical cancer screening. Our partnership with Techcyte and Tyrolpath demonstrates how innovation can be scaled to meet the needs of high-volume laboratories while laying the groundwork for broader diagnostic applications.' This implementation reflects a growing interest across Europe in modernizing cytology workflows through integrated, digital solutions. As partners explore the broader potential of AI and automation in laboratory diagnostics, this collaboration serves as an example of how technology and expertise can come together to support the evolving needs of clinical practice. Troy Bankhead Techcyte + +1 435 210-6200 email us here Visit us on social media: LinkedIn X Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Associated Press
20-03-2025
- Business
- Associated Press
Techcyte & Aiosyn Collaborate to Integrate AI-Powered Slide QC & Mitotic Counting into the Fusion™ Platform
'By integrating Aiosyn's slide QC and mitotic counting algorithms, we're enabling a more fluid, efficient workflow that reduces distractions and helps pathologists focus on making the right diagnosis.' — Ben Cahoon, CEO Techcyte OREM, UT, AND NIJMEGEN, NETHERLANDS, UT, UNITED STATES, March 20, 2025 / / -- Techcyte, a leader in digital pathology and Aiosyn, a leading developer of AI-driven pathology algorithms, today announced a collaboration that brings Aisoyn's AI algorithms to the Fusion digital pathology platform. Ensuring the quality of digital slides is a critical yet tedious and labor-intensive process for pathology labs. Aiosyn QC, Aiosyn's AI-based slide quality control (QC) algorithm detects and highlights common artifacts in H&E and IHC slides, helping laboratories present only high-quality images to pathologists. This streamlines pathology workflows, aiming to improve efficiency and enhance the accuracy of AI-assisted diagnostics by eliminating compromised or suboptimal images before pathologist review. 'High-quality imaging and AI-driven analysis are essential for advancing digital pathology,' said Patrick de Boer, CEO of Aiosyn. 'By bringing our slide QC and mitotic figure counting algorithms to Fusion, we're ensuring that pathologists not only work with optimal images, but also have access to advanced AI insights that support more confident decision-making.' Beyond slide QC, the collaboration also brings Aiosyn Mitosis Breast, Aiosyn's IVDR-certified mitotic counting algorithm for breast cancer images into the Fusion platform. Techcyte's Fusion Platform is uniquely designed to comprehensively integrate third-party AI solutions, ensuring that AI insights are seamlessly integrated into the clinical workflow. 'Fusion is designed to embed third-party AI directly into the pathology workflow, eliminating inefficiencies and ensuring that insights are accessible when and where pathologists need them,' said Ben Cahoon, CEO of Techcyte. 'By integrating Aiosyn's slide QC and mitotic counting algorithms, we're enabling a more fluid, efficient workflow that reduces distractions and helps pathologists focus on making the right diagnosis.' By combining Aiosyn's advanced pathology algorithms and Techcyte's Fusion digital pathology platform, this collaboration demonstrates the power of an open, standards-based, fully integrated AI-enabled digital pathology ecosystem. +1 435-210-6200 Legal Disclaimer:
